Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety Evaluation of Targeted Biopsy Plus Sextant Biopsy in Diagnosis of Prostate Cancer: a Randomized Controlled Trial

NCT06684652 is registered in ClinicalTrials.gov with Peking University First Hospital as lead sponsor.

NCT NCT06684652
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06684652 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety Evaluation of Targeted Biopsy Plus Sextant Biopsy in Diagnosis of Prostate Cancer: a Randomized Controlled Trial
Lead sponsor
Peking University First Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
December 1, 2024
Completion date
September 30, 2025
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer